-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17

Benzinga·09/15/2026 13:38:14
语音播报
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.